Pages that link to "Q35871689"
Jump to navigation
Jump to search
The following pages link to A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8 T cells and protects against herpes simplex virus type 2 challenge (Q35871689):
Displaying 50 items.
- Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown (Q21296712) (← links)
- The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine (Q27021292) (← links)
- Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen. (Q30468622) (← links)
- Induction of interferon-λ contributes to TLR3 and RIG-I activation-mediated inhibition of herpes simplex virus type 2 replication in human cervical epithelial cells (Q30683907) (← links)
- Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs (Q33595097) (← links)
- Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity (Q33614657) (← links)
- Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists (Q33721641) (← links)
- Nasolacrimal duct closure modulates ocular mucosal and systemic CD4( ) T-cell responses induced following topical ocular or intranasal immunization (Q33725145) (← links)
- Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8 T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes (Q33755236) (← links)
- Stepwise release of biologically active HMGB1 during HSV-2 infection (Q33809521) (← links)
- Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8 T-cell epitope-based vaccine (Q33993731) (← links)
- Prophylactic and therapeutic modulation of innate and adaptive immunity against mucosal infection of herpes simplex virus (Q34105712) (← links)
- Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8 T cells and reduces genital disease and viral shedding after HSV-2 challenge (Q34992660) (← links)
- Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice (Q35076638) (← links)
- HLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8 T cells from seropositive asymptomatic individuals and protect humanized HLA-A*02:01 transgeni (Q35122383) (← links)
- Of mice and not humans: How reliable are animal models for evaluation of herpes CD8 -T cell-epitopes-based immunotherapeutic vaccine candidates? (Q35173777) (← links)
- Phenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8 T cells from symptomatic and asymptomatic individuals with ocular herpes (Q35487893) (← links)
- Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8 T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of l (Q35745358) (← links)
- A Herpes Simplex Virus Type 1 Human Asymptomatic CD8 T-Cell Epitopes-Based Vaccine Protects Against Ocular Herpes in a "Humanized" HLA Transgenic Rabbit Model (Q35769258) (← links)
- Developing an asymptomatic mucosal herpes vaccine: the present and the future (Q35881975) (← links)
- The Herpes Simplex Virus Type 1 Latency-Associated Transcript Inhibits Phenotypic and Functional Maturation of Dendritic Cells (Q36005107) (← links)
- Future of an ‘Asymptomatic‘ T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine (Q36025675) (← links)
- Comparison of the host immune response to herpes simplex virus 1 (HSV-1) and HSV-2 at two different mucosal sites. (Q36155593) (← links)
- Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8 T cell immunity against herpes: importance of MyD88. (Q36339059) (← links)
- Strategies for intranasal delivery of vaccines (Q36514771) (← links)
- Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections (Q36520832) (← links)
- Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2. (Q36555158) (← links)
- The Herpes Simplex Virus Latency-Associated Transcript Gene Is Associated with a Broader Repertoire of Virus-Specific Exhausted CD8 T Cells Retained within the Trigeminal Ganglia of Latently Infected HLA Transgenic Rabbits (Q36736366) (← links)
- Protective effects of red ginseng extract against vaginal herpes simplex virus infection (Q36861306) (← links)
- Asymptomatic memory CD8 T cells: from development and regulation to consideration for human vaccines and immunotherapeutics (Q36977847) (← links)
- Novel approaches in fighting herpes simplex virus infections (Q37316071) (← links)
- New concepts in herpes simplex virus vaccine development: notes from the battlefield (Q37384857) (← links)
- FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection (Q37428262) (← links)
- TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes (Q37460727) (← links)
- Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8 TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocul (Q37560770) (← links)
- HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine (Q37611796) (← links)
- CD8 T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization (Q37679220) (← links)
- Toll-like receptors and genital tract infection (Q37705702) (← links)
- Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research (Q37712799) (← links)
- Insights into the role of Toll-like receptors in modulation of T cell responses (Q37777344) (← links)
- Female genital tract immunity: distinct immunological challenges for vaccine development (Q37966494) (← links)
- The ongoing pursuit of a prophylactic HSV vaccine (Q37991272) (← links)
- Modern subunit vaccines: development, components, and research opportunities (Q38073752) (← links)
- Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships (Q38153040) (← links)
- Targeting TLR2 for vaccine development (Q38233376) (← links)
- Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact (Q38279548) (← links)
- Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a. (Q39800428) (← links)
- Stimulation of human macrophages (THP-1) using Toll-like receptor-2 (TLR-2) agonist decorated nanocarriers (Q39810464) (← links)
- Synthetic peptides coupled to the surface of liposomes effectively induce SARS coronavirus-specific cytotoxic T lymphocytes and viral clearance in HLA-A*0201 transgenic mice (Q39843759) (← links)
- Intravaginal infection with herpes simplex virus type-2 (HSV-2) generates a functional effector memory T cell population that persists in the murine genital tract (Q39850112) (← links)